Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia

References

• Miehsler W, Gasche C. Standard therapy of Crohn's disease. Dig Dis 2003; 21: 146–56
   PubMed Web of Science ®Google Scholar
• Hanauer S. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582–92
   PubMed Web of Science ®Google Scholar
• Targan S, Hanauer S, Deventer SV, Mayer L, Present D, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029–35
   PubMed Web of Science ®Google Scholar
• Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, Hogezand RV, et al. Infliximab for the treatment of fistula in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, et al. Maintenance infliximab for Crohn's disease: the ACCENT randomized trial. Lancet 2002; 359: 1541–9
   PubMed Web of Science ®Google Scholar
• Cohen R, Tsang J, Hanauer S. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469–77
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus E, Tremaine W, Sandborn W. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients. Am J Gastroenterol 2001; 96: 722–9
   PubMed Web of Science ®Google Scholar
• Colombel J, Loftus E, Tremaine W, Egan L, Harmsen W, Zinmeister A, et al. The safety profile of infliximab in patients with Crohn's disease. Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31
   PubMed Web of Science ®Google Scholar
• Ljung T, Karlen P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease; clinical outcome in a population based cohort from Stockholm County. Gut 2003; 53: 849–53
   Web of Science ®Google Scholar
• Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman W, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098–104
   PubMed Web of Science ®Google Scholar
• Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 345: 1098–104
   PubMed Web of Science ®Google Scholar
• Brown S, Green M, Gershon S, Edwards E, Braun M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8
   PubMed Web of Science ®Google Scholar
• Everitt DE. Important drug warning: Centocor Inc; 2004 December.
   Google Scholar
• Sands B, Tremaine W, Sandborn W, Rutgeerts P, Hanauer S, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7: 83–8
   PubMed Web of Science ®Google Scholar
• Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998–1002
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805–11
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462–76
   PubMed Web of Science ®Google Scholar
• Geboes K. Histopathology of Crohn's disease and ulcerative colitis. Inflammatory bowel diseases1st ed, J Satsangi, LR Sutherland. Elsevier Limited, Philadelphia 2003; 255–76
   Google Scholar
• Van Deventer S. Tumor necrosis factor and Crohn's disease. Gut 1997; 40: 443–8
   PubMed Web of Science ®Google Scholar
• MacDonald T, Monteleone G, Pender S. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000; 51: 2–9
   PubMed Web of Science ®Google Scholar
• Fiocchi C. Inflammatory bowel disease; etiology and pathogenesis. Gastroenterology 1998; 115: 182–205
   PubMed Web of Science ®Google Scholar
• Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apheres 1998; 2: 134–41
   PubMedGoogle Scholar
• Ohara M, Saniabadi A, Kokuma S, Hirata I, Adachi M, Agishi T, et al. Granulocyte apheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997; 21: 989–94
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Sawada K, Tanaka T, Saito Y, Munakata A, Toyota T, , et al. Granulocyte and monocyte apheresis in patients with active ulcerative colitis. Jap J Apheres 1999.
   Google Scholar
• Saniabadi A, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apheres Dialys 2003; 7: 48–59
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Yoshimura N, Saniabadi A, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis; a prospective uncontrolled study. Dig Dis Sci 2004; 49: 565–71
   PubMed Web of Science ®Google Scholar
• Hanai H, Wantanabe F, Takeuchi K, Iida T, Yamada M, Iwoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis; a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003; 1: 28–35
   PubMed Web of Science ®Google Scholar
• Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocyte apheresis for Crohn's disease; a report on seven refractory patients. Am J Gastroenterol 2003; 98: 511–2
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yamagiwa A, Nakamura I, Nishikawa K, Saniabadi A. Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 2003; 98: 2101–2
   PubMed Web of Science ®Google Scholar
• Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004; 36: 811–7
   PubMedGoogle Scholar
• Dujorne C, Azarnoff D. Clinical complications of corticosteroid therapy. Med Clin North Am 1973; 57: 1331–42
   PubMed Web of Science ®Google Scholar
• Margolin M, Krumholz M, Fochios S, Korelitz B. Clinical trials in ulcerative colitis; II. Historical review. Am J Gastroenterol 1988; 83: 227–43
   PubMed Web of Science ®Google Scholar
• Truelove S, Witts L. Cortisone and corticotropin in ulcerative colitis. Br Med J 1959; 1: 387–94
   PubMed Web of Science ®Google Scholar
• Solem C, Loftus E, Tremaine W, Sandborn W. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97–101
   PubMed Web of Science ®Google Scholar
• Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocyte apheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004; 10: 251–7
   PubMed Web of Science ®Google Scholar
• Rubin D, Hanauer S. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 855–62
   PubMed Web of Science ®Google Scholar